Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia - Tabular View

Tracking Information
First Received Date ^ICMJE	March 26, 2004
Last Updated Date	August 21, 2008
Start Date ^ICMJE	November 2003
Primary Completion Date
Current Primary Outcome Measures ^ICMJE (submitted: August 21, 2008)	Change at endpoint in schizophrenia rating scale
Original Primary Outcome Measures ^ICMJE (submitted: September 9, 2005)	change at endpoint in schizophrania rating scale
Change History	Complete list of historical versions of study NCT00080327 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: September 9, 2005)	Clinical Global Improvement scale at endpoint and time to response
Original Secondary Outcome Measures ^ICMJE	Same as current

Descriptive Information
Brief Title ^ICMJE	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
Official Title ^ICMJE	A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
Brief Summary	A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
Detailed Description
Study Phase	Phase IV
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Condition ^ICMJE	Schizophrenia
Intervention ^ICMJE	Drug: Aripiprazole Drug: Placebo
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	370
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Men and women, ages 18 and older, with a worsening of schizophrenia symptoms over the past three months
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00080327
Responsible Party
Study ID Numbers ^ICMJE	CN138-113 ST
Study Sponsor ^ICMJE	Bristol-Myers Squibb
Collaborators ^ICMJE	Otsuka America Pharmaceutical
Investigators ^ICMJE
Information Provided By	Bristol-Myers Squibb
Verification Date	August 2008
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP